Sodium Phenylbutyrate

The molecule's HDACenzymes that switch genes off by tightening DNA packaging inhibition is real but mild compared with the dedicated cancer drugs in this class; at the doses used clinically much of its action comes from its second job as a chemical chaperone. When misfolded proteins pile up inside the ER, the cell triggers the "unfolded protein response," a stress program that, if it runs too hard or too long, pushes cells toward death. Sodium 4-phenylbutyrate physically stabilizes folding intermediates and blunts that response; in a classic experiment it rescued cells expressing misfolded myocilin (a glaucoma protein) from ER-stress-driven apoptosis ^[1], and in animal models it eased ER stress in the heart during doxorubicin (chemotherapy) injury ^[2] and dampened airway inflammation in experimental asthma ^[3].

Its approved use is unrelated to the brain. In urea cycle disorders the body cannot clear ammonia normally; phenylbutyrate is converted to phenylacetate, which latches onto the amino acid glutamine and is excreted, carrying nitrogen out of the body along a path that bypasses the broken urea cycle ^[4]. That ammonia-scavenging role is well established. The neuroscience interest rides on the chaperone and epigenetic effects, and it culminated in AMX0035, phenylbutyrate plus taurursodiol, aimed at protecting motor neurons in ALS by relieving both ER stress and mitochondrialrelating to mitochondria, the cell's power plants stress. The mid-stage CENTAUR trial reported a slower decline in function ^[5], which supported an approval, but the story did not hold up; reviews of the combination flagged how much rested on that single modest trial ^[6][7], and the larger confirmatory study later failed to show benefit, after which the product was withdrawn. So the honest summary is that the chemistry is genuinely interesting, but the human evidence in neurodegeneration did not survive a proper test.